Read More

CCHFVaccine, initially planned as a six-year project launched in January 2017 and coordinated by Folkhälsomyndigheten (the Public Institute of Sweden, FoHM, Professor Ali Mirazimi) in Sweden, has now been extended to eight years.

This extension aims to ensure the successful launch of a phase 1 trial in humans. Consequently, the project end date is now set for December 2024.

It's worth noting that there is already confirmation of a continuation project, known as CCHFVACIM.

Our collaborative network brings together 14 complementary partners, including 13 research institution and one technology transfer / management company.

The project is supported by the European Commission under the H2020 Programme

 

A collaborative network


 

tique  American continent

USA - Heinrich Feldmann

National Institute of Health

tique  Asian continent

Tajikistan - Farida Tishkova

Tajik Research Institute of Preventive Medicine

 






tique  European continent

Bulgaria - Iva Christova

National Center of Infectiousand Parasitic Diseases

France - Anna Boitard

Inserm Transfert

Germany - Martin Groschup

Friederich - Loeffler - Institut

Germany - Friedemann Weber

Justus-Liebig University

Germany - Veronika von Messling

Paul-Ehrlich-Institut

Kosovo - Isme Humolli

National Institute of Public Health

UK - Roger Hewson

Department of Health, Public Health England

Turkey - Nazif Elaldi

Cumhuriyet Universtitesi

Turkey - Zati Vatansever

Kafkas Universitesi

Sweden - Ali Mirazimi

Folkhälsomyndigheten

Sweden - Matti Sallberg

Karolinska Institutet

Sweden - Rickard Knutsson

Statens Veterinärmedicinska Anstalt

 

 

 

 

map large